L-Base Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 21, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,233,221 | Peptide Having Eight Amino Acid Sequences Derived from Cage and Retaining Anticancer Activity and Activity to Promote Anticancer Drug Sensitivity of Anticancer Drug-Resistant Cancer Cells In force · Low confidence | In force | Low confidence | |
| US 10,239,924 | Peptide Having Eight Amino Acid Sequences Derived from Cage and Retaining Anticancer Activity and Activity to Promote Anticancer Drug Sensitivity of Anticancer Drug-Resistant Cancer Cells In force · High confidence | In force | High confidence | |
| US 10,716,826 | Compositions for overcoming anti-cancer drug-resistance or compositions for anti-cancer activity employing CAGE-derived peptides In force · USPTO record | In force | USPTO record | |
| US 10,766,926 | Composition for autophagy inhibiting in cell, and pharmaceutical composition for preventing or treating tumor disease, or inhibiting anti-cancer agents resistance containing the same In force · USPTO record | In force | USPTO record | |
| US 12,048,730 | Pharmaceutical composition for preventing or treating cancer, containing oligopeptide as active ingredient In force · USPTO record | In force | USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 3 no status recorded
Showing 1 to 5 of 5, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/692,883 | Sep 16, 2022 | No status recorded | |
| 18/550,775 | Pharmaceutical Composition for Enhancing Anticancer Effect of Anticancer Drug | Mar 16, 2022 | Abandoned |
| 17/996,875 | Pharmaceutical Composition for Preventing or Treating Cancer | Feb 25, 2022 | Pending |
| 16/945,382 | Jul 31, 2020 | No status recorded | |
| 17/608,263 | Apr 29, 2020 | No status recorded |